Receptor binding assay for NO-independent activators of soluble guanylate cyclase

Methods in Molecular Biology

Volumn 1020, Issue , 2013, Pages 205-214

  Schmidt, Peter M ^a   Stasch, Johannes Peter ^b  

^a CSL LIMITED   (Australia)

^b BAYER PHARMA AG   (Germany)

Author keywords

BAY 58 2667; Binding constant; cinaciguat; Filter plates; Radioligand; Receptor binding assay; riociguat; sGC; Soluble guanylate cyclase

Indexed keywords

CINACIGUAT; GUANYLATE CYCLASE; NITRIC OXIDE;

ARTICLE; BINDING AFFINITY; BINDING SITE; ENZYME SUBSTRATE COMPLEX; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 84883181413     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-459-3_13     Document Type: Article

References (28)

1. Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bosse R, Bielefeld M (2008) The use of AlphaScreen technology in HTS: Current status. Curr Chem Genomics 1:2-10
2. Ullman EF, Kirakossian H, Singh S, Wu ZP, Irvin BR, Pease JS, Switchenko AC, Irvine JD, Dafforn A, Skold CN et al (1994) Luminescent oxygen channeling immunoassay: Measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 91(12):5426-5430
3. Bazin H, Trinquet E, Mathis G (2002) Time resolved ampli fication of cryptate emission: A versatile technology to trace biomolecular interactions. J Biotechnol 82(3):233-250
4. Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B (2009) HTRF: A technology tailored for drug discovery-a review of theoretical aspects and recent applications. Curr Chem Genomics 3:22-32
5. Olson KR, Eglen RM (2007) Beta galactosidase complementation: A cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol 5(1):137-144
6. Rothkegel C, Schmidt PM, Atkins DJ, Hoffmann LS, Schmidt HH, Schroder H, Stasch JP (2007) Dimerization region of soluble guanylate cyclase characterized by bimolecular fl uorescence complementation in vivo. Mol Pharmacol 72(5):1181-1190
7. Jason-Moller L, Murphy M, Bruno J (2006) Overview of Biacore systems and their applications. Current protocols in protein science Chapter 19:Unit 19.14. doi: 10.1002/0471142301 .ps1914s45
8. Navratilova I, Hopkins AL (2011) Emerging role of surface plasmon resonance in fragmentbased drug discovery. Future Med Chem 3(14):1809-1820
9. Glickman JF, Schmid A, Ferrand S (2008) Scintillation proximity assays in high-throughput screening. Assay Drug Dev Technol 6(3):433-455
10. O'Neill MA, Gaisford S (2011) Application and use of isothermal calorimetry in pharmaceutical development. Int J Pharm 417(1-2):83-93
11. Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S (2011) Molecular interaction studies using microscale thermophoresis. Assay Drug Dev Technol 9(4):342-353
12. Schmidt PM (2009) Biochemical detection of cGMP from past to present: An overview. Handb Exp Pharmacol 191:195-228
13. Schmidt P, Schramm M, Schroder H, Stasch JP (2003) Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase. Anal Biochem 314(1):162-165
14. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F (2002) NO- and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136(5):773-783
15. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Kumar HSA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116(9):2552-2561
16. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, Stasch JP (2009) Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 157(5):781-795
17. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat Rev 5(9):755-768
18. Schmidt HH, Schmidt PM, Stasch JP (2009) NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 191:309-339
19. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R (2010) Kynurenine is an endothelium-derived relaxing factor produced during in fl ammation. Nat Med 16(3): 279-285
20. Hahn MG, Alonso-Alija C, Stoll F, Heil M, Mittendorf M, Schlemmer KH, Wunder F, Stasch JP (2007) Design and synthesis of thefirst NO- and haem-independent sGC activator BAY 58-2667 for the treatment of acute decompensated heart failure. BMC Pharmacol 7:P25
21. Seidel D, Pleiss U (2010) Labelling of the guanylate cyclase activator cinaciguat (BAY 58-2667) with carbon-14, tritium and stable isotopes. J Label Compd Radiopharm 53:130-139
22. Scott CW, Gomes BC, Hubbs SJ, Koenigbauer HC (1995) Afiltration-based assay to quantitate granulocyte-macrophage colony-stimulating factor binding. Anal Biochem 228(1):150-154
23. Demoliou-Mason CD, Barnard EA (1984) Solubilization in high yield of opioid receptors retaining high-affinity delta, mu and kappa binding sites. FEBS Lett 170(2):378-382
24. Atha DH, Ingham KC (1981) Mechanism of precipitation of proteins by polyethylene glycols. Analysis in terms of excluded volume. J Biol Chem 256(23):12108-12117
25. Bhat R, Timasheff SN (1992) Steric exclusion is the principal source of the preferential hydration of proteins in the presence of polyethylene glycols. Protein Sci 1(9):1133-1143
26. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP (2004) Identi fication of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279(4):3025-3032
27. Foerster J, Harteneck C, Malkewitz J, Schultz G, Koesling D (1996) A functional hemebinding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. Eur J Biochem 240(2):380-386
28. Schmidt P, Schramm M, Schroder H, Stasch JP (2003) Preparation of heme-free soluble guanylate cyclase. Protein Expr Purif 31(1):42-46